ABSTRACT
An immunological examination of patients with septic cholangitis revealed secondary immunodeficiency. Traditional methods of therapy and immunocorrection were ineffective in eight patients with septic cholangitis. They were treated with extracorporeal immunopharmacotherapy using diuciphon. For the accomplishing detoxication, this was used in combination with plasma exchange. The course of treatment consisted of 3 or 4 procedures, within a 3- or 4-day interval. As a result of extracorporeal immunocorrection, patients were observed to have positive immunological indexes, demonstrated by the normalization of the lymphocyte count in 5 of 6 patients, CD3+ and CD4+ in 3 patients, and CD8+ in 4. Four patients had clinical remissions (0.5 year), and 3 patients underwent surgery with no septic postoperative complications.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Cholangitis/therapy , Immunotherapy, Adoptive/methods , Plasma Exchange , Sulfones/therapeutic use , Uracil/analogs & derivatives , Adult , Aged , Cholangitis/immunology , Cholangitis/microbiology , Drug Combinations , Female , Humans , Male , Middle Aged , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/immunology , Uracil/therapeutic useABSTRACT
Unlike hemocarboperfusion (HCP), plasmapheresis (PA) produces a long-term effect in the treatment of serious cases of rheumatoid arthritis. This explains why the rebound syndrome occurs in PA two times less frequently. The analysis of the immunomodifying action of both the treatments and comparison of their efficacy suggest the conclusion that long-term and complete remissions are associated with the immunosuppressive effects, while the development of exacerbations accompanies the immunomodifying effect. HCP stimulates the immune system, while PA can induce both stimulation and suppression. Therefore, HCP can be used as an adjuvant treatment of highly active rheumatoid arthritis before the basic therapy. In PA immunosuppressive effect, it may be used as an original treatment method.
